LEU

Centrus Energy is positioned as an attractive nuclear investment opportunity due to its dominant position as the only HALEU enricher in the Western World. With a $4.5 billion backlog of LEU and HALEU sales commitments and a $2.4 billion market cap, the company could potentially grow tenfold as advanced reactor makers scale operations, offering significant wealth-building potential without needing to build reactors itself.

Centrus Energy, the only public U.S. company selling high-assay low-enriched uranium (HALEU), benefits from growing nuclear energy demand driven by AI and cloud computing. However, the stock faces near-term challenges: analysts expect revenue and net income to decline through 2028 as the company restarts domestic operations before the Russian uranium import ban takes effect. At 40x forward earnings, the stock is expensive and unlikely to create significant wealth in the near term despite its strategic market position.

Centrus Energy's stock has plummeted 69% from its October 2025 high of $464.25 to $143, despite holding a robust $4.5 billion backlog. While the company benefits from growing nuclear demand and is the only U.S. public producer of HALEU fuel, near-term challenges persist: revenue is expected to decline through 2028, most backlog orders won't convert to revenue until the late 2020s, and capital-intensive expansion plans will pressure earnings. At 50x forward earnings, the stock appears expensive and lacks near-term catalysts.